Mink parvovirus attenuated vaccine strain and application of mink parvovirus attenuated vaccine strain in preparation of mink parvovirus attenuated vaccine

A technology of mink parvovirus and attenuated vaccine, applied in antiviral agents, viruses/phages, microorganism-based methods, etc., can solve problems such as hidden dangers of vaccine use in the next step, incomplete inactivation, and impact on the quality of mink skins.

Active Publication Date: 2015-03-04
INST OF SPECIAL ANIMAL & PLANT SCI OF CAAS
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, most of the existing mink parvovirus enteritis vaccines in the domestic market are inactivated vaccines that have not been freeze-dried. In the production process of inactivated vaccines, the inactivation is often incomplete or the use of inactivating agents (mostly formaldehyde) exceeds the standard. , which brings great hidden dangers to the next use of the vaccine
At the same time, formaldehyde is highly toxic, so the use of formaldehyde as an inactivator has certain toxicity to minks, often causing local inflammatory reactions at the inoculation site, even suppuration, ulcers, affecting the quality of mink fur and causing economic losses.
At the same time, inactivated vaccines can only mobilize the body's humoral immunity, but cannot stimulate the generation of the body's cellular immune response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Passage weakening of mink parvovirus MEVB

[0020] 1. Passage weakening of mink parvovirus MEVB

[0021] (1) The mink parvovirus vaccine strain MEVB was inoculated on cat kidney cells CRFK by synchronous inoculation for virus amplification and culture, and the cell lesion was observed every day. When the cell lesion reached about 80%, it could be frozen and thawed repeatedly. The virus was harvested using the method described above and labeled MEVB-F1 (passage 1).

[0022] (2) The first-generation virus MEVB-F1 was inoculated and harvested according to the method described above, and the virus was labeled as MEVB-F2 (second generation). Using the same method, the virus was passaged to passage 61, labeled as MEVB-F61.

[0023] (3) When the mink parvovirus MEVB was continuously passaged to the 10th generation (MEVB-F10), the virus was cloned and plaque-purified. The method is: dilute the virus to be purified 10 times to 10 -7 , take 10 -3 ~10 -7 0.1ml of v...

Embodiment 2

[0032] The preparation of embodiment 2 mink parvovirus enteritis live vaccine

[0033](1) Vaccine strain MEVB-F61 was inoculated on CRFK cells synchronously according to 0.1%-2% of the culture volume, and cultured in a 35°C spinner. Methods Harvest virus liquid. Five batches of vaccines were prepared according to the above method, and the virus content and purity were tested. The results showed that the virus titers (TCID) of the five batches of vaccines 50 )≥10 6.5 / ml, indicating that the vaccine strain MEVB-F61 has good production performance and is suitable for large-scale industrial production.

[0034] (2) Preparation of lyoprotectant

[0035] Dissolving gelatin, hydrolyzed milk protein and sucrose in water, according to the mass percentage, the final concentration of gelatin is 2-7%, the final concentration of hydrolyzed milk protein is 10-25%, and the final concentration of sucrose is 15-30%. Obtained after autoclaving at 116°C for 30 minutes.

[0036] (3) Mix th...

Embodiment 3

[0038] Example 3 Mink Parvovirus Enteritis Live Vaccine Safety Test

[0039] Get 3 batches of qualified mink parvovirus enteritis live vaccines (prepared by the method of embodiment 2), hindlimb muscle inoculation antibody negative mink, carry out single dose respectively (10 5.5 / head portion), single-dose repeated and over-dose (10 times) inoculation, while non-vaccinated mink was set as a control. After the vaccination, the body temperature, appetite, mental state and other physiological indicators of the minks were observed for 14 consecutive days, and the intestinal lesions of the vaccinated minks were observed by autopsy. The test results showed that after single-dose, repeated single-dose and over-dose vaccination, all the physiological indexes of the minks were normal, without any clinical symptoms, and there was no pathological change in the intestinal tract of the vaccinated mink. It shows that mink parvovirus enteritis live vaccine is safe for mink.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a mink parvovirus attenuated vaccine strain and application of the mink parvovirus attenuated vaccine strain in preparation of a mink parvovirus attenuated vaccine. The mink parvovirus attenuated vaccine strain is named as MEVB-F61 and preserved in the China General Microbiological Culture Collection Center, and the preservation number of the mink parvovirus attenuated vaccine strain is CGMCC No.9560. A test result shows that when used as a vaccine, the vaccine strain is safe and effective, and prevents the mink parvovirus enteritis effectively, and no reversion to virulence of the vaccine strain is realized through inoculation experiments of continuous five generations of animals. Therefore, the mink parvovirus attenuated vaccine strain has a wide application prospect in the field of preventing mink parvovirus enteritis.

Description

technical field [0001] The invention relates to mink parvovirus attenuated vaccine strain and its application, and the invention belongs to the technical field of veterinary biological products Background technique [0002] Mink parvovirus enteritis is an acute and highly contagious infectious disease caused by parvovirus in the family Parvoviridae. Together with canine distemper and Aleutian disease in mink, it is called the three major diseases of mink farming. The disease was first reported by Schofield in 1949 and found in Canada. It was isolated and identified by Wills in 1952 and named as mink enteritis virus. Currently, mink parvovirus enteritis widely exists in various mink raising countries in the world. Minks of different ages and varieties are susceptible, but especially young minks and young minks aged 50 to 60 days are the most susceptible. The incidence rate of young minks is over 70%, and the mortality rate is as high as 90%. It is about 30%, and the mortalit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/00A61K39/23A61P31/20C12R1/93
Inventor 闫喜军胡博柴秀丽张海玲张蕾赵建军白雪刘昊
Owner INST OF SPECIAL ANIMAL & PLANT SCI OF CAAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap